BioSpace News Archive

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented new SQZ™ AAC and eAPC preclinical research describing the robust potential of these platforms to treat cancer, including data demonstrating synergistic activity when combined with chemotherapy.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), today announced final Phase 1b data for EDP-514, a novel pangenotypic class II hepatitis B virus (HBV) core inhibitor, in conjunction with two posters presented at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD).

LENSAR, Inc. today announced that two posters have been accepted for virtual presentation at the Annual Meeting of the American Academy of Ophthalmology (AAO)

PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Xencor Presents Data from Multiple Preclinical XmAb ® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting

Nurix Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has cleared Nurix’s Investigational New Drug Application (IND) for its lead cell therapy product candidate DeTIL-0255

NexImmune, Inc. today reported its financial results for the third quarter of 2021.

GenScript USA Inc announced today that it has launched the GenWand™ Double-Stranded DNA (dsDNA) Service for the manufacture of CRISPR knock-in homology- directed repair (HDR) templates in T cell engineering.

Amgen (NASDAQ: AMGN) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT